Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IMA 901

Next Previous
Drug Profile

IMA 901

Alternative Names: IMA-901; Renal cancer vaccine - Immatics N.V.

Latest Information Update: 07 Jul 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator immatics biotechnologies GmbH
  • Class Cancer vaccines; Peptide vaccines; Peptides
  • Mechanism of Action CD4-positive T lymphocyte stimulants; CD8 positive T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Renal cell carcinoma
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Renal cell carcinoma

Most Recent Events

  • 01 Jul 2020 Immatics N.V and Immatics Biotechnologies GmbH combined to form Immatics N.V.
  • 03 May 2016 Discontinued - Phase-II for Renal cell carcinoma (Combination therapy, Late-stage disease, Second-line therapy or greater) in Spain, Switzerland, Slovakia, Bulgaria, Austria (Intradermal) (Immatics pipeline, May 2016)
  • 03 May 2016 Discontinued - Phase-III for Renal cell carcinoma (Combination therapy, First-line therapy, Late-stage disease) in Germany, USA, France, Hungary, Italy, Netherlands, Norway, Poland, Romania, Russia, United Kingdom (Intradermal) (Immatics pipeline, May 2016)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top